{"ticker": {"uuid": "bd5ea6d2-0456-4243-b93a-fa060a62c128", "symbol": "GHRS", "name": "GH Research PLC", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Price-Driven Insight from (GHRS) for Rule-Based Strategy", "summary": "This article provides a price-driven analysis of Gh Research Plc (NASDAQ: GHRS) for developing a rule-based trading strategy. It highlights strong sentiment supporting an overweight bias and identifies key support and resistance levels across multiple time horizons. The analysis ", "url": "https://news.stocktradersdaily.com/news_release/39/Price-Driven_Insight_from_GHRS_for_Rule-Based_Strategy_071926124601_1784436361.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-19T00:46:00", "published_display": "19 Jul 2026 00:46", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research : GHRS", "summary": "This article provides an overview of GH Research PLC (GHRS), a Dublin-based biopharmaceutical company specializing in treatments for psychiatric and neurological disorders using 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies, particularly for treatment-resistant depressio", "url": "https://247wallst.com/companies/GHRS/?tpid=1626040&tv=link&tc=in_content", "source_name": "24/7 Wall St.", "published_at": "2026-07-17T16:11:13", "published_display": "17 Jul 2026 16:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GHR Research PLC stock hits 52-week high at $30.20", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPbUtKaXh5LXVtMmJBQVY1Ulo1M2xPaFNXUENFYTlLSEQyWThJS1N5NUFaTTV0WlVyWkVub3hDRHhpNV8tWGZMYXNHcHdVb3ZjU09wenpiUG1Melp0SE1lbzNueUxDWDJnNVhRQXN2X0pGWVhseTB3X2FudUhZN1NkOE5vV2dLWk9EWXNJNUptRWd4UWlsU3NSYUROLTFLdmhsY0c0eG4zUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-07-17T03:22:22+00:00", "published_display": "17 Jul 2026 03:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Is GH Research Stock Trading Higher on Thursday?", "summary": "GH Research (GHRS) stock is trading higher due to Eli Lilly's agreement to acquire AtaiBeckley Inc. (ATAI) for up to $3.8 billion. GH Research's lead drug, GH001, is being compared to AtaiBeckley\u2019s BPL-003, both targeting treatment-resistant depression with similar active compoun", "url": "https://www.benzinga.com/m-a/26/07/60504723/why-is-gh-research-stock-trading-higher-on-thursday", "source_name": "Benzinga", "published_at": "2026-07-16T16:41:56", "published_display": "16 Jul 2026 16:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research PLC (GHRS:UW): Stock Price, Quote and News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTE9yN0ZJVzAzdG5lbm5meENRTXZhQTNoZkxvT05ma0RkSFZhRERJUFI2aEwzZDg0ejYyaS03eHFmTDRxOWI3QXRRYzJVSjBxSW1rQ3djMg?oc=5", "source_name": "BNN Bloomberg", "published_at": "2026-07-16T15:41:36+00:00", "published_display": "16 Jul 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research stock jumps on Eli Lilly-Atai acquisition talks", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOQUlyRXh6RHU5S21HWW9LdG1qLUVWUEhSVy0zZmVacU9keDR2RlItVTFqeUZOVXdTR1J1TW9zbE5qamJVWWJsM1RQbmFCMlFKUkxuUkZMYWt4Q08td2dRTjlHdGM3ak95YklFbHhYbnd3RkdlU3h3dGV6YUcxRXBGSUJnVmh6dXN6Uk9XU19RWE1vcHhIQTR5elZNUTFicDNhYnhEM05fcFN2c2VYZXFCaWJsV0ZZMm1qaTBZZA?oc=5", "source_name": "Investing.com", "published_at": "2026-07-16T14:37:30+00:00", "published_display": "16 Jul 2026 14:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research (GHRS) In Focus As FDA Psychedelic Shift Raises The Question Of Value", "summary": "The FDA's recent guidance on psychedelic drug development has significantly boosted GH Research (GHRS) stock, with its share price up over 100% year-to-date. Despite this surge, the company's valuation, evidenced by a 7x price-to-book ratio, appears expensive compared to its peer", "url": "https://www.sahmcapital.com/news/content/gh-research-ghrs-in-focus-as-fda-psychedelic-shift-raises-the-question-of-value-2026-07-15", "source_name": "Sahm", "published_at": "2026-07-16T11:42:24", "published_display": "16 Jul 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is GH Research stock surging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQUHI2cWd1aWFyeV91UzFjaE4wNlFtc3NlSXJDLU1saXBjd2FNcHhkQkFIb3dZMEk5RnRFQlh6TDZGUzdHSkJJZWNySVpzMXFDZEo4eUlUQm4wdE9TRHhMNjNtRkJNbm5wS1RJUUQ0SFdReFNsTWlJLVVJaFh4cklYSDJSd013WEpOMzVibFhTdGFyYVVXVk5kdkRxd1N4a2RPcmc?oc=5", "source_name": "Investing.com", "published_at": "2026-07-16T09:48:17+00:00", "published_display": "16 Jul 2026 09:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS)", "summary": "GH Research (GHRS) shares rose about 12% following reports that Eli Lilly is discussing acquiring Atai Life Sciences (ATAI), a psychedelic drug developer. This news boosted the entire psychedelic medicines sector, as investors anticipate increased pharmaceutical interest in such ", "url": "https://finance.yahoo.com/healthcare/articles/gh-research-gains-optimism-surrounding-103351818.html", "source_name": "Market source", "published_at": "2026-07-16T10:33:00", "published_display": "16 Jul 2026 10:33", "sentiment": "positive", "sentiment_pct": 77, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GH Research (GHRS) price target increased by 18.94% to 40.04", "summary": "This article reports a significant increase in the price target for GH Research (GHRS), which has been raised by 18.94% to $40.04. This adjustment indicates a positive outlook from analysts regarding the company's future stock performance.", "url": "http://www.msn.com/en-us/money/topstocks/gh-research-ghrs-price-target-increased-by-18-94-to-40-04/ar-AA1ZAPb9?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-10T16:09:36", "published_display": "10 Jul 2026 16:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A3CUAZ Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for GH Research Plc (A3CUAZ) stock, including analyst price targets and ratings. It states that 8 analysts offer a 1-year price forecast, with current price, historical performance, and future earning estimates. The article also answers frequently", "url": "https://www.tradingview.com/symbols/LSX-A3CUAZ/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-07-10T09:40:10", "published_display": "10 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of GH Research PLC \u2013 NASDAQ:GHRS", "summary": "This article from TradingView presents the \"Price to book forward\" financial metric for GH Research PLC (NASDAQ:GHRS). It provides financial data and other information related to the company's stock performance. The content is primarily a data presentation page on the TradingView", "url": "https://www.tradingview.com/symbols/NASDAQ-GHRS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T16:41:27", "published_display": "06 Jul 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of GH Research PLC \u2013 NASDAQ:GHRS", "summary": "This article focuses on the \"Price to sales forward\" metric for GH Research PLC (NASDAQ: GHRS) within the financial analysis section of TradingView. It provides specific financial data for the company, indicating the period, value, change, and percentage change for this particula", "url": "https://www.tradingview.com/symbols/NASDAQ-GHRS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T15:12:33", "published_display": "06 Jul 2026 15:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of GH Research PLC \u2013 NASDAQ:GHRS", "summary": "This article provides financial data specifically on the enterprise value to revenue forward of GH Research PLC (NASDAQ:GHRS). It appears to be a stub or data-point focused entry, offering a snapshot of a particular financial metric for the company. The content primarily presents", "url": "https://www.tradingview.com/symbols/NASDAQ-GHRS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T11:43:28", "published_display": "06 Jul 2026 11:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GHRS - GH Research PLC Options", "summary": "This article provides a comprehensive financial overview of GH Research PLC (GHRS), detailing its stock performance, key financial metrics, and insider/institutional ownership. It highlights the company's recent closing price, market capitalization, earnings per share, and variou", "url": "https://finviz.com/stock?t=GHRS&ta=1&p=d&ty=oc&b=1", "source_name": "Finviz", "published_at": "2026-07-04T02:09:36", "published_display": "04 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH RESEARCH PLC (GHRS) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE1BVkhrX3NGdnAzMFRnVXM2N2NCNHVoT2FZejFEM0ZQX2hOZ2VXUzYyU2c4aG1WYzNZcDA0anFWb2pMRUh1dWlhakVNVUV6X21jU01wdndJMzBQaEF6R1VpVTFlbE4?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T00:00:01+00:00", "published_display": "03 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research Plc Actuals & Estimates (FWB:1KA)", "summary": "This article provides financial actuals and estimates for GH Research Plc (FWB:1KA), including income statement, balance sheet, cash flow, and valuation metrics. It highlights analyst price targets, historical stock data, upcoming earnings reports, and details on recent earnings ", "url": "https://www.tradingview.com/symbols/FWB-1KA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-28T03:10:37", "published_display": "28 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pre-Market Movement | GH Research Shares Surge to 52-Week High", "summary": "GH Research shares experienced a significant surge in pre-market trading, reaching a new 52-week high of $12.37. This substantial increase was driven by the company's positive announcement regarding its GH001 program for treating depression, which reported an 87.5% remission rate", "url": "https://news.futunn.com/en/post/75195821/pre-market-movement-gh-research-shares-surge-to-52-week", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-27T13:10:37", "published_display": "27 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GHRS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for GH Research PLC (GHRS) stock, indicating a price target of $39.13 based on analyst reports. It details the company's recent stock performance, noting a significant increase over the past year, and includes analyst estimates for", "url": "https://www.tradingview.com/symbols/NASDAQ-GHRS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T20:39:14", "published_display": "26 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(GHRS) Price Dynamics and Execution-Aware Positioning", "summary": "This article analyzes the price dynamics and execution-aware positioning for Gh Research Plc (NASDAQ: GHRS). It highlights strong near-term sentiment, potential for higher levels, and no resistance above the current price, suggesting upside potential. The report also details thre", "url": "https://news.stocktradersdaily.com/news_release/24/GHRS_Price_Dynamics_and_Execution-Aware_Positioning_062626041401_1782504841.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-26T16:39:14", "published_display": "26 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research PLC stock hits 52-week high at 25.98 USD", "summary": "GH Research PLC stock has reached a new 52-week high of $25.98, reflecting a 104% increase over the past year and strong investor confidence. The company, valued at $1.77 billion, recently reported positive Phase 2a trial results for its inhaled mebufotenin (GH001) in postpartum ", "url": "https://www.investing.com/news/company-news/gh-research-plc-stock-hits-52week-high-at-2598-usd-93CH-4762970", "source_name": "Investing.com", "published_at": "2026-06-26T15:10:27", "published_display": "26 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research PLC (GHRS) re-elects directors and ratifies PwC Ireland at AGM", "summary": "GH Research PLC announced the results of its annual general meeting held on June 25, 2026. Shareholders approved all resolutions, including the re-election of four directors\u2014Florian Sch\u00f6nharting, Michael Forer, Dermot Hanley, and Duncan Moore\u2014and the ratification of Pricewaterhou", "url": "https://www.stocktitan.net/sec-filings/GHRS/6-k-gh-research-plc-current-report-foreign-issuer-274c2ae3b244.html", "source_name": "Stock Titan", "published_at": "2026-06-26T11:10:27", "published_display": "26 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GHRS Stock Price and Chart \u2014 NASDAQ:GHRS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBDbDBfUnZOT1BSeUFtN1dBWnIwd2JMRkFhanBqdUsyU3RsTkpqMXVYTmZXM3JSaW9BS19WY1hzNS0zbG8zbFpBUy1Zc29yX3Q3dTY3YzVRbEdMaXhm?oc=5", "source_name": "TradingView", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research Plc Actuals & Estimates (MUN:1KA)", "summary": "This article provides an overview of GH Research Plc (MUN:1KA) financial actuals and estimates, including its stock ticker, analyst price forecasts, historical price performance, and upcoming earnings dates. It details recent earnings and revenue figures, notes that the company d", "url": "https://www.tradingview.com/symbols/MUN-1KA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T15:42:42", "published_display": "25 Jun 2026 15:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research PLC (GHRS) Valuation: PE, PB & Fair Value Analysis", "summary": "This article from TradingKey provides a valuation analysis for GH Research PLC (GHRS). It notes that relevant data for key valuation metrics such as P/E, P/B, P/S, and P/CF have not yet been disclosed by the company. The article focuses on the current stock price and market capit", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ghrs/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:49", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research PLC (GHRS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for GH Research PLC (GHRS), highlighting analyst ratings and target prices. Based on 9 analysts, the company has a \"Buy\" rating with a target price of $39.50, representing a 97.70% upside. It also details past and future EPS expectations", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ghrs/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:09:00", "published_display": "18 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What GH Research (GHRS)'s Phase 2a Postpartum Depression Breakthrough Means For Shareholders", "summary": "GH Research (GHRS) has reported positive Phase 2a results for its inhaled Mebufotenin (GH001) in postpartum depression, showing rapid remission in all ten patients and a favorable safety profile. This breakthrough strengthens the company's investment narrative for a niche psychia", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/what-gh-research-ghrss-phase-2a-postpartum-depression-breakt", "source_name": "Simply Wall Street", "published_at": "2026-06-17T22:40:49", "published_display": "17 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research PLC (GHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses the revenue breakdown of GH Research PLC (GHRS) by business segments and regional contributions. However, it explicitly states that the relevant financial data has not yet been disclosed by the company. As a result, the content indicates that no specific rev", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ghrs/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T10:39:54", "published_display": "17 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(GHRS) as a Liquidity Pulse for Institutional Tactics", "summary": "This article provides an analysis of Gh Research Plc (NASDAQ: GHRS) using AI models, outlining a weak near and mid-term sentiment but a strong long-term outlook. It details three trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014with specific entry, target,", "url": "https://news.stocktradersdaily.com/news_release/34/GHRS_as_a_Liquidity_Pulse_for_Institutional_Tactics_061526030202_1781550122.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-15T15:02:00", "published_display": "15 Jun 2026 15:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research (GHRS) Stock Valuation After Positive Phase 2a Mebufotenin Data In Postpartum Depression", "summary": "GH Research (GHRS) has released positive Phase 2a data for its mebufotenin treatment in postpartum depression, yet its stock has seen a slight decline over the past month. Despite strong longer-term share price performance, the company remains loss-making with no current revenue ", "url": "https://www.sahmcapital.com/news/content/gh-research-ghrs-stock-valuation-after-positive-phase-2a-mebufotenin-data-in-postpartum-depression-2026-06-15", "source_name": "Sahm", "published_at": "2026-06-15T08:39:35", "published_display": "15 Jun 2026 08:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Do GH Research\u2019s (GHRS) Phase 2a Postpartum Data Subtly Reframe Its Broader Depression Strategy?", "summary": "GH Research (GHRS) recently published positive Phase 2a results for inhaled Mebufotenin (GH001) in postpartum depression, showing rapid remission and good tolerability. While these results strengthen the medical case for GH001 across depressive disorders, the market remains conce", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/do-gh-researchs-ghrs-phase-2a-postpartum-data-subtly-reframe", "source_name": "Simply Wall Street", "published_at": "2026-06-11T04:39:43", "published_display": "11 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Buy Rating on GH Research (GHRS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNbXBHNlNSWU95VlF5X3JWZXhGQWx2NUhBeEp2bWtEOXpTSy1iUVVVTXFBak9oblZOYlNWN3ZfS3g2YV90MFktYVZEclBZNE9EaHVTQldZTzNGVktETi1BM2Yya3ZPLVdyMjZTYmhPVVRyMXVVWVRiRTJoemp2bGNaS1kzUUc4T2wtT2pzR0xUU1JRLXVqTlRUbg?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research Announces Publication of Phase 2a Postpartum Depression Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gh-research-announces-publication-phase-110000438.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T11:00:00+00:00", "published_display": "04 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright lowers GH Research stock price target on dilution", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQZGlvSWZudmhMeDNpakJVaGJySjlvSEZMcG95UTM2M0tHRWdScWktb0hJVkhXS3NmOGI0empWWGxpRG04eHRNZHI0NDgycThsVXZlM0ZrMXB1UWxXVDZUUWlVQVdpWTdLT2xjSVotQ25wQVRGVmRaNXQ4eFNvbTBsb3BmbF9Ec0E4ODEwdXpTbENCZThsWUJpcFNRQkZ6RV95aEd6X0IzMUJfelVMU2d6NUd6OTQzaEdNck1jcUpVcnQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing GH Research (GHRS) Valuation After Key Phase 2b Results And Phase 3 Trial Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaGFLWDdHUnlrN29uUWlXNFFzVklOdmEyVUZYaHR5SDBvZVNoQW5icjNZMG1Lc1Vlczk2WHhURjhlUmthMkp6X05MOFBjdTZMSG1LaDI5ZnZucFdUSDhRV3RxOHprVS1HU0taVFpuTTRPcndGd1k2UkxkeXZ1a0Mzc3E5eEdjeU9IQ0dycE9aZmlBVS1YMzJfbnVwcExxVFNwY1JmbU1DNEc?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GH Research Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxPaGNDNzVySlNJTXJ4cUlGU0dUbGRwVW54OFZGWmhBZGllWEtEZkFCeW5jdEl1MW5KamJBSVNxRFF6Q1VCSl95THV6RFJoczdTeXlkVTBVemVGMjIxUU51Z0UySGtvTjNabVZfYnFxSXc3aEFrbmRnRDRxSGwxaW1vanZzcU1yZnZLazlDbXdwcVMzbU4wNjQydjVZcmR6dlNJNFQ5aFkxREtaUFA4YTBpUVZFanNPRkxLWDdYSXNUQy1SaVJiT3ViRnNvZ0JnNmRPc3JfR0xzVDlrUUFiX3B2SjBPc3h2emNQUmJhRS13?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GH Research Announces Pricing of $117.5 Million Underwritten Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQMlhKdS1DdW9qeG9nREYwbGdkYnN1cFB4R1F5UUcwNEtJNF9JUjJyN09rYlBBTGg4MG5CelRFS3hqMXZUUjQ3b1V6eDNBX0FhcVJGWUZ0cl9HanBfcHF5T3ZsbF90ZW1xVEtER3NSZjZ1Q1VYOFV6dDFSZW5Ma2Y1M1FLOWVWaUpEbkJHWkRBX081SjdqOWJFeURpdWVzRjlKb21VSEJMcmRaWFlYXzlIZ2RWYURIZ3JsUmphYkpfSktSemFwQ0t5dnBIUmUyYzRHeHp0TXVn?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "White House mental illness order aligns with GH Research's 2026 Phase 3 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNMXFab2tJZGpMNldyUk5VSy11Z0loOVBmN0pvNFN3ZVYxMGg5RXgzRjZSd3BtZUZPVmVEN25tbXA2OFRyWTZ2V2ZwbTE1WlJ6eWpKamR0dkJWalNTenlJU0dnZkhVNVhpcVplaXQ5LVFvTXNPSXd4THpySDFWM2dYVEg5MURoVWZFMy02aGt3RkhFZ1NhcDNRQ20xckhPblU3NEJJcktzaERfd2dGdXpiNF84Nm1oTXZs?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not At All Concerned With GH Research's (NASDAQ:GHRS) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOdE4tZmpSOVc2TXNnZVQ2VDAxLXQ3b1Q1QjRRejZablJKNEI4VkZFZTFCTE5iUFEtdHYwVGFtOUFpT1FXYm92VjkwVnQzVVZKVjV2a05fdDVDZnVneXlOUUlJUC1ETUpOZEZLZzcxWTNGcnpXd3V6ZW9qT3NURkFTNnBYZ2JPYkZuUjJQanU1cTRLY21fZkpxYQ?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela\u2014 GH Research", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogJBVV95cUxPM1BobXR2bHhaOEtHZVNDMEFHaWVoTDYtcmVGV1puXzVNWU5JYXRuTTV1bjRvb3UzeTJBWUhOWVhwaElEN2Fqck9LcjZRc3FlSEhQYlRxdW8waXg5LXNXdmc1QmdOaFp5cExnS3U2Rm5Lb3FSbWhKSHJHRDFqZDdTcTVaVW5zbmFKeHVQNnB5LUdRcmlkNFdSdFB3SVVSTzlXQjJSZUlvRk1wb1BZM0NkWHluM0pWZTJMYjJZbEdZSnRiZkFHMC1mbzR3UW1NNFZMdk5HbE10SExxTWRhT2E2c3hINEc0OVVaMnJoeEFNNU4yUWlzek1aZFZnel94RUE4c1JkRzFvVlRUekVRVXBPNjcwNm0zSDZ2OXFDQW5uMHhHUQ?oc=5", "source_name": "Benzinga", "published_at": "2026-01-05T08:00:00+00:00", "published_display": "05 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNNDdXQnE3R3V5SERrVHQ5dllWR1VaUXM5X2dMVUZPaEhyRTR4cnJUaDdoQjlMdGFMSVd0Wi1EczNSbEtpNXpZRXpVdzlRVV9KRmpXVU9WaHRZMm9GZzNDNF84WFppVVdhVDhWUGdlV0F2NDA4NnA1SFIwem9fNUVqbGdseXJGSHA1Qzgwd0ZNeUk1dmw3bHZGbUctTjFFcTU3dkxiYW4yZGcyYkg2RFhNbUZyYUhwakxRZTJLczNsRU83Qjl3dFdLUW1ocE9Jb3JXbHNfYUl6Q0Q4d3hsU2NnZjVR?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-05T08:00:00+00:00", "published_display": "05 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price-Driven Insight from (GHRS) for Rule-Based Strategy", "summary": "This article provides a price-driven analysis of Gh Research Plc (NASDAQ: GHRS) for developing a rule-based trading strategy. It highlights strong sentiment supporting an overweight bias and identifies key support and resistance levels across multiple time horizons. The analysis ", "url": "https://news.stocktradersdaily.com/news_release/39/Price-Driven_Insight_from_GHRS_for_Rule-Based_Strategy_071926124601_1784436361.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-19T00:46:00", "published_display": "19 Jul 2026 00:46", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research : GHRS", "summary": "This article provides an overview of GH Research PLC (GHRS), a Dublin-based biopharmaceutical company specializing in treatments for psychiatric and neurological disorders using 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies, particularly for treatment-resistant depressio", "url": "https://247wallst.com/companies/GHRS/?tpid=1626040&tv=link&tc=in_content", "source_name": "24/7 Wall St.", "published_at": "2026-07-17T16:11:13", "published_display": "17 Jul 2026 16:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GHR Research PLC stock hits 52-week high at $30.20", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPbUtKaXh5LXVtMmJBQVY1Ulo1M2xPaFNXUENFYTlLSEQyWThJS1N5NUFaTTV0WlVyWkVub3hDRHhpNV8tWGZMYXNHcHdVb3ZjU09wenpiUG1Melp0SE1lbzNueUxDWDJnNVhRQXN2X0pGWVhseTB3X2FudUhZN1NkOE5vV2dLWk9EWXNJNUptRWd4UWlsU3NSYUROLTFLdmhsY0c0eG4zUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-07-17T03:22:22+00:00", "published_display": "17 Jul 2026 03:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is GH Research Stock Trading Higher on Thursday?", "summary": "GH Research (GHRS) stock is trading higher due to Eli Lilly's agreement to acquire AtaiBeckley Inc. (ATAI) for up to $3.8 billion. GH Research's lead drug, GH001, is being compared to AtaiBeckley\u2019s BPL-003, both targeting treatment-resistant depression with similar active compoun", "url": "https://www.benzinga.com/m-a/26/07/60504723/why-is-gh-research-stock-trading-higher-on-thursday", "source_name": "Benzinga", "published_at": "2026-07-16T16:41:56", "published_display": "16 Jul 2026 16:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research PLC (GHRS:UW): Stock Price, Quote and News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTE9yN0ZJVzAzdG5lbm5meENRTXZhQTNoZkxvT05ma0RkSFZhRERJUFI2aEwzZDg0ejYyaS03eHFmTDRxOWI3QXRRYzJVSjBxSW1rQ3djMg?oc=5", "source_name": "BNN Bloomberg", "published_at": "2026-07-16T15:41:36+00:00", "published_display": "16 Jul 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research stock jumps on Eli Lilly-Atai acquisition talks", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOQUlyRXh6RHU5S21HWW9LdG1qLUVWUEhSVy0zZmVacU9keDR2RlItVTFqeUZOVXdTR1J1TW9zbE5qamJVWWJsM1RQbmFCMlFKUkxuUkZMYWt4Q08td2dRTjlHdGM3ak95YklFbHhYbnd3RkdlU3h3dGV6YUcxRXBGSUJnVmh6dXN6Uk9XU19RWE1vcHhIQTR5elZNUTFicDNhYnhEM05fcFN2c2VYZXFCaWJsV0ZZMm1qaTBZZA?oc=5", "source_name": "Investing.com", "published_at": "2026-07-16T14:37:30+00:00", "published_display": "16 Jul 2026 14:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research (GHRS) In Focus As FDA Psychedelic Shift Raises The Question Of Value", "summary": "The FDA's recent guidance on psychedelic drug development has significantly boosted GH Research (GHRS) stock, with its share price up over 100% year-to-date. Despite this surge, the company's valuation, evidenced by a 7x price-to-book ratio, appears expensive compared to its peer", "url": "https://www.sahmcapital.com/news/content/gh-research-ghrs-in-focus-as-fda-psychedelic-shift-raises-the-question-of-value-2026-07-15", "source_name": "Sahm", "published_at": "2026-07-16T11:42:24", "published_display": "16 Jul 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is GH Research stock surging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQUHI2cWd1aWFyeV91UzFjaE4wNlFtc3NlSXJDLU1saXBjd2FNcHhkQkFIb3dZMEk5RnRFQlh6TDZGUzdHSkJJZWNySVpzMXFDZEo4eUlUQm4wdE9TRHhMNjNtRkJNbm5wS1RJUUQ0SFdReFNsTWlJLVVJaFh4cklYSDJSd013WEpOMzVibFhTdGFyYVVXVk5kdkRxd1N4a2RPcmc?oc=5", "source_name": "Investing.com", "published_at": "2026-07-16T09:48:17+00:00", "published_display": "16 Jul 2026 09:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS)", "summary": "GH Research (GHRS) shares rose about 12% following reports that Eli Lilly is discussing acquiring Atai Life Sciences (ATAI), a psychedelic drug developer. This news boosted the entire psychedelic medicines sector, as investors anticipate increased pharmaceutical interest in such ", "url": "https://finance.yahoo.com/healthcare/articles/gh-research-gains-optimism-surrounding-103351818.html", "source_name": "Market source", "published_at": "2026-07-16T10:33:00", "published_display": "16 Jul 2026 10:33", "sentiment": "positive", "sentiment_pct": 77, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research (GHRS) price target increased by 18.94% to 40.04", "summary": "This article reports a significant increase in the price target for GH Research (GHRS), which has been raised by 18.94% to $40.04. This adjustment indicates a positive outlook from analysts regarding the company's future stock performance.", "url": "http://www.msn.com/en-us/money/topstocks/gh-research-ghrs-price-target-increased-by-18-94-to-40-04/ar-AA1ZAPb9?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-10T16:09:36", "published_display": "10 Jul 2026 16:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A3CUAZ Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for GH Research Plc (A3CUAZ) stock, including analyst price targets and ratings. It states that 8 analysts offer a 1-year price forecast, with current price, historical performance, and future earning estimates. The article also answers frequently", "url": "https://www.tradingview.com/symbols/LSX-A3CUAZ/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-07-10T09:40:10", "published_display": "10 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of GH Research PLC \u2013 NASDAQ:GHRS", "summary": "This article from TradingView presents the \"Price to book forward\" financial metric for GH Research PLC (NASDAQ:GHRS). It provides financial data and other information related to the company's stock performance. The content is primarily a data presentation page on the TradingView", "url": "https://www.tradingview.com/symbols/NASDAQ-GHRS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T16:41:27", "published_display": "06 Jul 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of GH Research PLC \u2013 NASDAQ:GHRS", "summary": "This article focuses on the \"Price to sales forward\" metric for GH Research PLC (NASDAQ: GHRS) within the financial analysis section of TradingView. It provides specific financial data for the company, indicating the period, value, change, and percentage change for this particula", "url": "https://www.tradingview.com/symbols/NASDAQ-GHRS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T15:12:33", "published_display": "06 Jul 2026 15:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of GH Research PLC \u2013 NASDAQ:GHRS", "summary": "This article provides financial data specifically on the enterprise value to revenue forward of GH Research PLC (NASDAQ:GHRS). It appears to be a stub or data-point focused entry, offering a snapshot of a particular financial metric for the company. The content primarily presents", "url": "https://www.tradingview.com/symbols/NASDAQ-GHRS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T11:43:28", "published_display": "06 Jul 2026 11:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GHRS - GH Research PLC Options", "summary": "This article provides a comprehensive financial overview of GH Research PLC (GHRS), detailing its stock performance, key financial metrics, and insider/institutional ownership. It highlights the company's recent closing price, market capitalization, earnings per share, and variou", "url": "https://finviz.com/stock?t=GHRS&ta=1&p=d&ty=oc&b=1", "source_name": "Finviz", "published_at": "2026-07-04T02:09:36", "published_display": "04 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH RESEARCH PLC (GHRS) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE1BVkhrX3NGdnAzMFRnVXM2N2NCNHVoT2FZejFEM0ZQX2hOZ2VXUzYyU2c4aG1WYzNZcDA0anFWb2pMRUh1dWlhakVNVUV6X21jU01wdndJMzBQaEF6R1VpVTFlbE4?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T00:00:01+00:00", "published_display": "03 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research Plc Actuals & Estimates (FWB:1KA)", "summary": "This article provides financial actuals and estimates for GH Research Plc (FWB:1KA), including income statement, balance sheet, cash flow, and valuation metrics. It highlights analyst price targets, historical stock data, upcoming earnings reports, and details on recent earnings ", "url": "https://www.tradingview.com/symbols/FWB-1KA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-28T03:10:37", "published_display": "28 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pre-Market Movement | GH Research Shares Surge to 52-Week High", "summary": "GH Research shares experienced a significant surge in pre-market trading, reaching a new 52-week high of $12.37. This substantial increase was driven by the company's positive announcement regarding its GH001 program for treating depression, which reported an 87.5% remission rate", "url": "https://news.futunn.com/en/post/75195821/pre-market-movement-gh-research-shares-surge-to-52-week", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-27T13:10:37", "published_display": "27 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GHRS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for GH Research PLC (GHRS) stock, indicating a price target of $39.13 based on analyst reports. It details the company's recent stock performance, noting a significant increase over the past year, and includes analyst estimates for", "url": "https://www.tradingview.com/symbols/NASDAQ-GHRS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T20:39:14", "published_display": "26 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(GHRS) Price Dynamics and Execution-Aware Positioning", "summary": "This article analyzes the price dynamics and execution-aware positioning for Gh Research Plc (NASDAQ: GHRS). It highlights strong near-term sentiment, potential for higher levels, and no resistance above the current price, suggesting upside potential. The report also details thre", "url": "https://news.stocktradersdaily.com/news_release/24/GHRS_Price_Dynamics_and_Execution-Aware_Positioning_062626041401_1782504841.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-26T16:39:14", "published_display": "26 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research PLC stock hits 52-week high at 25.98 USD", "summary": "GH Research PLC stock has reached a new 52-week high of $25.98, reflecting a 104% increase over the past year and strong investor confidence. The company, valued at $1.77 billion, recently reported positive Phase 2a trial results for its inhaled mebufotenin (GH001) in postpartum ", "url": "https://www.investing.com/news/company-news/gh-research-plc-stock-hits-52week-high-at-2598-usd-93CH-4762970", "source_name": "Investing.com", "published_at": "2026-06-26T15:10:27", "published_display": "26 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research PLC (GHRS) re-elects directors and ratifies PwC Ireland at AGM", "summary": "GH Research PLC announced the results of its annual general meeting held on June 25, 2026. Shareholders approved all resolutions, including the re-election of four directors\u2014Florian Sch\u00f6nharting, Michael Forer, Dermot Hanley, and Duncan Moore\u2014and the ratification of Pricewaterhou", "url": "https://www.stocktitan.net/sec-filings/GHRS/6-k-gh-research-plc-current-report-foreign-issuer-274c2ae3b244.html", "source_name": "Stock Titan", "published_at": "2026-06-26T11:10:27", "published_display": "26 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GHRS Stock Price and Chart \u2014 NASDAQ:GHRS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBDbDBfUnZOT1BSeUFtN1dBWnIwd2JMRkFhanBqdUsyU3RsTkpqMXVYTmZXM3JSaW9BS19WY1hzNS0zbG8zbFpBUy1Zc29yX3Q3dTY3YzVRbEdMaXhm?oc=5", "source_name": "TradingView", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research Plc Actuals & Estimates (MUN:1KA)", "summary": "This article provides an overview of GH Research Plc (MUN:1KA) financial actuals and estimates, including its stock ticker, analyst price forecasts, historical price performance, and upcoming earnings dates. It details recent earnings and revenue figures, notes that the company d", "url": "https://www.tradingview.com/symbols/MUN-1KA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T15:42:42", "published_display": "25 Jun 2026 15:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research PLC (GHRS) Valuation: PE, PB & Fair Value Analysis", "summary": "This article from TradingKey provides a valuation analysis for GH Research PLC (GHRS). It notes that relevant data for key valuation metrics such as P/E, P/B, P/S, and P/CF have not yet been disclosed by the company. The article focuses on the current stock price and market capit", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ghrs/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:49", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research PLC (GHRS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for GH Research PLC (GHRS), highlighting analyst ratings and target prices. Based on 9 analysts, the company has a \"Buy\" rating with a target price of $39.50, representing a 97.70% upside. It also details past and future EPS expectations", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ghrs/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:09:00", "published_display": "18 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What GH Research (GHRS)'s Phase 2a Postpartum Depression Breakthrough Means For Shareholders", "summary": "GH Research (GHRS) has reported positive Phase 2a results for its inhaled Mebufotenin (GH001) in postpartum depression, showing rapid remission in all ten patients and a favorable safety profile. This breakthrough strengthens the company's investment narrative for a niche psychia", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/what-gh-research-ghrss-phase-2a-postpartum-depression-breakt", "source_name": "Simply Wall Street", "published_at": "2026-06-17T22:40:49", "published_display": "17 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research PLC (GHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses the revenue breakdown of GH Research PLC (GHRS) by business segments and regional contributions. However, it explicitly states that the relevant financial data has not yet been disclosed by the company. As a result, the content indicates that no specific rev", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ghrs/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T10:39:54", "published_display": "17 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(GHRS) as a Liquidity Pulse for Institutional Tactics", "summary": "This article provides an analysis of Gh Research Plc (NASDAQ: GHRS) using AI models, outlining a weak near and mid-term sentiment but a strong long-term outlook. It details three trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014with specific entry, target,", "url": "https://news.stocktradersdaily.com/news_release/34/GHRS_as_a_Liquidity_Pulse_for_Institutional_Tactics_061526030202_1781550122.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-15T15:02:00", "published_display": "15 Jun 2026 15:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research (GHRS) Stock Valuation After Positive Phase 2a Mebufotenin Data In Postpartum Depression", "summary": "GH Research (GHRS) has released positive Phase 2a data for its mebufotenin treatment in postpartum depression, yet its stock has seen a slight decline over the past month. Despite strong longer-term share price performance, the company remains loss-making with no current revenue ", "url": "https://www.sahmcapital.com/news/content/gh-research-ghrs-stock-valuation-after-positive-phase-2a-mebufotenin-data-in-postpartum-depression-2026-06-15", "source_name": "Sahm", "published_at": "2026-06-15T08:39:35", "published_display": "15 Jun 2026 08:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Do GH Research\u2019s (GHRS) Phase 2a Postpartum Data Subtly Reframe Its Broader Depression Strategy?", "summary": "GH Research (GHRS) recently published positive Phase 2a results for inhaled Mebufotenin (GH001) in postpartum depression, showing rapid remission and good tolerability. While these results strengthen the medical case for GH001 across depressive disorders, the market remains conce", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/do-gh-researchs-ghrs-phase-2a-postpartum-data-subtly-reframe", "source_name": "Simply Wall Street", "published_at": "2026-06-11T04:39:43", "published_display": "11 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Buy Rating on GH Research (GHRS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNbXBHNlNSWU95VlF5X3JWZXhGQWx2NUhBeEp2bWtEOXpTSy1iUVVVTXFBak9oblZOYlNWN3ZfS3g2YV90MFktYVZEclBZNE9EaHVTQldZTzNGVktETi1BM2Yya3ZPLVdyMjZTYmhPVVRyMXVVWVRiRTJoemp2bGNaS1kzUUc4T2wtT2pzR0xUU1JRLXVqTlRUbg?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research Announces Publication of Phase 2a Postpartum Depression Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gh-research-announces-publication-phase-110000438.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T11:00:00+00:00", "published_display": "04 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright lowers GH Research stock price target on dilution", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQZGlvSWZudmhMeDNpakJVaGJySjlvSEZMcG95UTM2M0tHRWdScWktb0hJVkhXS3NmOGI0empWWGxpRG04eHRNZHI0NDgycThsVXZlM0ZrMXB1UWxXVDZUUWlVQVdpWTdLT2xjSVotQ25wQVRGVmRaNXQ4eFNvbTBsb3BmbF9Ec0E4ODEwdXpTbENCZThsWUJpcFNRQkZ6RV95aEd6X0IzMUJfelVMU2d6NUd6OTQzaEdNck1jcUpVcnQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing GH Research (GHRS) Valuation After Key Phase 2b Results And Phase 3 Trial Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaGFLWDdHUnlrN29uUWlXNFFzVklOdmEyVUZYaHR5SDBvZVNoQW5icjNZMG1Lc1Vlczk2WHhURjhlUmthMkp6X05MOFBjdTZMSG1LaDI5ZnZucFdUSDhRV3RxOHprVS1HU0taVFpuTTRPcndGd1k2UkxkeXZ1a0Mzc3E5eEdjeU9IQ0dycE9aZmlBVS1YMzJfbnVwcExxVFNwY1JmbU1DNEc?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxPaGNDNzVySlNJTXJ4cUlGU0dUbGRwVW54OFZGWmhBZGllWEtEZkFCeW5jdEl1MW5KamJBSVNxRFF6Q1VCSl95THV6RFJoczdTeXlkVTBVemVGMjIxUU51Z0UySGtvTjNabVZfYnFxSXc3aEFrbmRnRDRxSGwxaW1vanZzcU1yZnZLazlDbXdwcVMzbU4wNjQydjVZcmR6dlNJNFQ5aFkxREtaUFA4YTBpUVZFanNPRkxLWDdYSXNUQy1SaVJiT3ViRnNvZ0JnNmRPc3JfR0xzVDlrUUFiX3B2SjBPc3h2emNQUmJhRS13?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research Announces Pricing of $117.5 Million Underwritten Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQMlhKdS1DdW9qeG9nREYwbGdkYnN1cFB4R1F5UUcwNEtJNF9JUjJyN09rYlBBTGg4MG5CelRFS3hqMXZUUjQ3b1V6eDNBX0FhcVJGWUZ0cl9HanBfcHF5T3ZsbF90ZW1xVEtER3NSZjZ1Q1VYOFV6dDFSZW5Ma2Y1M1FLOWVWaUpEbkJHWkRBX081SjdqOWJFeURpdWVzRjlKb21VSEJMcmRaWFlYXzlIZ2RWYURIZ3JsUmphYkpfSktSemFwQ0t5dnBIUmUyYzRHeHp0TXVn?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "White House mental illness order aligns with GH Research's 2026 Phase 3 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNMXFab2tJZGpMNldyUk5VSy11Z0loOVBmN0pvNFN3ZVYxMGg5RXgzRjZSd3BtZUZPVmVEN25tbXA2OFRyWTZ2V2ZwbTE1WlJ6eWpKamR0dkJWalNTenlJU0dnZkhVNVhpcVplaXQ5LVFvTXNPSXd4THpySDFWM2dYVEg5MURoVWZFMy02aGt3RkhFZ1NhcDNRQ20xckhPblU3NEJJcktzaERfd2dGdXpiNF84Nm1oTXZs?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not At All Concerned With GH Research's (NASDAQ:GHRS) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOdE4tZmpSOVc2TXNnZVQ2VDAxLXQ3b1Q1QjRRejZablJKNEI4VkZFZTFCTE5iUFEtdHYwVGFtOUFpT1FXYm92VjkwVnQzVVZKVjV2a05fdDVDZnVneXlOUUlJUC1ETUpOZEZLZzcxWTNGcnpXd3V6ZW9qT3NURkFTNnBYZ2JPYkZuUjJQanU1cTRLY21fZkpxYQ?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela\u2014 GH Research", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogJBVV95cUxPM1BobXR2bHhaOEtHZVNDMEFHaWVoTDYtcmVGV1puXzVNWU5JYXRuTTV1bjRvb3UzeTJBWUhOWVhwaElEN2Fqck9LcjZRc3FlSEhQYlRxdW8waXg5LXNXdmc1QmdOaFp5cExnS3U2Rm5Lb3FSbWhKSHJHRDFqZDdTcTVaVW5zbmFKeHVQNnB5LUdRcmlkNFdSdFB3SVVSTzlXQjJSZUlvRk1wb1BZM0NkWHluM0pWZTJMYjJZbEdZSnRiZkFHMC1mbzR3UW1NNFZMdk5HbE10SExxTWRhT2E2c3hINEc0OVVaMnJoeEFNNU4yUWlzek1aZFZnel94RUE4c1JkRzFvVlRUekVRVXBPNjcwNm0zSDZ2OXFDQW5uMHhHUQ?oc=5", "source_name": "Benzinga", "published_at": "2026-01-05T08:00:00+00:00", "published_display": "05 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNNDdXQnE3R3V5SERrVHQ5dllWR1VaUXM5X2dMVUZPaEhyRTR4cnJUaDdoQjlMdGFMSVd0Wi1EczNSbEtpNXpZRXpVdzlRVV9KRmpXVU9WaHRZMm9GZzNDNF84WFppVVdhVDhWUGdlV0F2NDA4NnA1SFIwem9fNUVqbGdseXJGSHA1Qzgwd0ZNeUk1dmw3bHZGbUctTjFFcTU3dkxiYW4yZGcyYkg2RFhNbUZyYUhwakxRZTJLczNsRU83Qjl3dFdLUW1ocE9Jb3JXbHNfYUl6Q0Q4d3hsU2NnZjVR?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-05T08:00:00+00:00", "published_display": "05 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 50, "sentiment_summary": {"positive": 15, "negative": 2, "neutral": 33, "score": 57, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 75, "events": [{"event": "earnings", "label": "Earnings", "weight": 11.41, "count": 23}, {"event": "general", "label": "Market update", "weight": 9.7, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 28.71, "latest_week": "2026-07-17", "one_week_move": 8.3, "four_week_move": 29.1, "twelve_week_move": 41.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.584978, "market_dynamics_buy_signal": false, "relative_strength": 58.207534, "fair_value_gap": 136.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 50.4846, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+8.3% over one week, +29.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "TradingView", "count": 9}, {"label": "Investing.com", "count": 5}, {"label": "Stock Traders Daily", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Benzinga", "count": 2}, {"label": "Sahm", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 41}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 23}, {"label": "Market update", "count": 17}, {"label": "Analyst action", "count": 4}, {"label": "Guidance", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "41", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+8.3% over one week, +29.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Price-Driven Insight from (GHRS) for Rule-Based Strategy"}], "updated_at": "2026-07-21T22:32:53.687492+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}